| Authors: |
Piperno-Neumann S; Institut Curie, Paris, France. sophie.piperno-neumann@curie.fr., Larkin J; Royal Marsden NHS Foundation Trust, London, United Kingdom., Carvajal RD; Memorial Sloan Kettering Cancer Center, New York, New York., Luke JJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Schwartz GK; Memorial Sloan Kettering Cancer Center, New York, New York., Hodi FS; Dana-Farber Cancer Institute, Boston, Massachusetts., Sablin MP; Institut Curie, Paris, France., Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, New York., Szpakowski S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Chowdhury NR; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Brannon AR; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Ramkumar T; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., de Koning L; Institut Curie, Paris, France., Derti A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Emery C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Yerramilli-Rao P; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Kapiteijn E; Leiden University Medical Centre, Department of Medical Oncology, Leiden, the Netherlands. |